AC Immune
Clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases
AC Immune has raised €77M across 3 funding rounds, most recently a Series D+ round in May 2016. Based in Lausanne, Switzerland; founded 2003; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€77M
€76,545,455
Funding rounds
3
Investors
0
distinct backers
Active since
2005-05
latest 2016-05
Funding by year
EUR raised per yearAC Immune — funding by year — interactive chart.
Data table
| AC Immune — funding by year | |
|---|---|
| 2005 | €19M |
| 2013 | €18M |
| 2016 | €40M |
Signals
Medium confidenceRaise-next likelihood12
base rate 53% for Series D+
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
Exit likelihood6
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▼ Old (23y) — past typical exit age
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2016-05-01 | Series D+ | €40M | — | View deal → |
| 2014-01-01 | Series D+ | €18M | — | View deal → |
| 2005-05-01 | Series B | €19M | — | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData